U.S. Urological Device Market to Reach $3.8 Billion by 2025, Led by Boston Scientific and BARD – New Study by iData Research

VANCOUVER, British Columbia–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/marketresearch?src=hash" target="_blank"gt;#marketresearchlt;/agt;–According to the latest series of reports by iData
Research, the United States urological device market is valued at
over $2.9 billion, and is expected to reach $3.8 billion by 2025. The
total market value includes multiple segments, such as urinary
incontinence devices, stone management devices, benign prostate
hyperplasia (BPH) treatment devices, urological endoscopes, prostate
cancer treatment devices, urodynamic equipment, nephrostomy devices and
erectile dysfunction devices.

The U.S. urology market is largely driven by the aging population. The
majority of stone management procedures, urinary incontinence incidence
and BPH incidence are prevalent in patients over the age of 45, a
steadily growing demographic. However, each area is also governed by
different market dynamics that affect the level of growth exhibited by
each procedure type.

Get A Free Sample Analysis from The U.S.
Market Report Suite for Urological Devices

The largest segment of the U.S. urological device market is the urinary
incontinence market. Growth of this segment is primarily driven by the
urinary catheter market, due to the high-volume use of urinary
catheters. The incidence of urinary incontinence generally increases
with age. As a result, urinary
incontinence statistics show the volume of treatments increasing
along with the aging population and rising life expectancy. In the
elderly, urinary incontinence may result from a confluence of factors,
including comorbid conditions, medications, and neuro-urinary pathology,
among others.

“In addition, the benign prostate hyperplasia (BPH) treatment market is
the fastest growing in the urology market, with a CAGR reaching over 9%.
This growth is primarily being driven by two new innovative products, UroLift
and Rezūm, which are continuing to cannibalize other, more
established treatments, such as laser systems and transurethral
resection of the prostate (TURP),” explains Jeffrey Wong, Analyst
Director at iData Research.

Boston Scientific is the leading competitor in the urological device
market. The company held the leading positions in the stone management
device market, BPH treatment device market and erectile dysfunction
market. Although a few years old now, Boston Scientific’s most recent
innovation was the inception of the single-use flexible ureteroscope,
with the launch of LithoVue™ in 2016.

Following Boston Scientific, BARD was the second-leading competitor. The
company held the leading position in the urinary incontinence device
market, solely attributed to its dominant position in the urinary
catheter market. BARD also held notable positions in the stone
management device market, prostate cancer device market and nephrostomy
device market.

For Further Market Information

More can be found in a series of reports published by iData Research
entitled the US
Market Report Suite for Urological Devices– MedSuite.

Email us at [email protected] or
register
online for a brochure and synopsis.

About iData

iData
Research is an international consulting and market research firm
dedicated to empowering confident strategic decisions within the medical
device, dental, and pharmaceutical industries.

Contacts

Joel Harrison
604-266-6933
[email protected]